MX2018000013A - Composiciones y metodos para diagnosis y tratamiento de anemia. - Google Patents

Composiciones y metodos para diagnosis y tratamiento de anemia.

Info

Publication number
MX2018000013A
MX2018000013A MX2018000013A MX2018000013A MX2018000013A MX 2018000013 A MX2018000013 A MX 2018000013A MX 2018000013 A MX2018000013 A MX 2018000013A MX 2018000013 A MX2018000013 A MX 2018000013A MX 2018000013 A MX2018000013 A MX 2018000013A
Authority
MX
Mexico
Prior art keywords
methods
compositions
anemia
treatment
conditions
Prior art date
Application number
MX2018000013A
Other languages
English (en)
Inventor
Baird Mark
Kay Venn-Watson Stephanie
Original Assignee
The United States 0F America As Represented By The Secretary 0F The Navy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The United States 0F America As Represented By The Secretary 0F The Navy filed Critical The United States 0F America As Represented By The Secretary 0F The Navy
Publication of MX2018000013A publication Critical patent/MX2018000013A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se proporcionan composiciones que incluyen un ácido graso, tal como un ácido graso de cadena impar o un ácido graso de cadena par muy larga, y sales y derivados de los mismos, y métodos para el tratamiento y profilaxis de condiciones relacionadas a condiciones anémicas, que incluyen composiciones y métodos para tratar condiciones anémicas tal como anemia hemolítica y anemia de enfermedad crónica, y otras condiciones relacionadas.
MX2018000013A 2016-12-29 2018-01-08 Composiciones y metodos para diagnosis y tratamiento de anemia. MX2018000013A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15/393,771 US10238618B2 (en) 2016-12-29 2016-12-29 Compositions and methods for diagnosis and treatment of anemia

Publications (1)

Publication Number Publication Date
MX2018000013A true MX2018000013A (es) 2018-11-09

Family

ID=61022302

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018000013A MX2018000013A (es) 2016-12-29 2018-01-08 Composiciones y metodos para diagnosis y tratamiento de anemia.
MX2020004767A MX2020004767A (es) 2016-12-29 2018-01-08 Composiciones y metodos para diagnosis y tratamiento de anemia.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2020004767A MX2020004767A (es) 2016-12-29 2018-01-08 Composiciones y metodos para diagnosis y tratamiento de anemia.

Country Status (7)

Country Link
US (3) US10238618B2 (es)
EP (2) EP3562481B1 (es)
JP (1) JP7037367B2 (es)
CA (1) CA3039591A1 (es)
ES (1) ES2899635T3 (es)
MX (2) MX2018000013A (es)
WO (1) WO2018122407A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9561206B2 (en) * 2015-01-07 2017-02-07 The United States Of America, As Represented By The Secretary Of The Navy Use of heptadecanoic acid (C17:0) to detect risk of and treat hyperferritinemia and metabolic syndrome
US10307388B2 (en) * 2016-12-29 2019-06-04 The United States Of America As Represented By The Secretary Of The Navy Compositions and methods for diagnosis and treatment of inflammation
JP7312184B2 (ja) 2017-10-23 2023-07-20 エピトラッカー インコーポレイテッド 脂肪酸アナログおよび代謝症候群に関連する症状の処置におけるそれらの使用
JP2021525249A (ja) 2018-05-23 2021-09-24 エピトラッカー インコーポレイテッドＥｐｉｔｒａｃｋｅｒ， Ｉｎｃ． 加齢及び長期性の質に関連する状態の診断及び治療のための組成物及び方法
US20230172917A1 (en) * 2020-07-01 2023-06-08 The Board Of Trustees Of The Leland Stanford Junior University Methods of Treating Bone Marrow Failure Syndromes and Compositions for Use in the Same

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR79620E (fr) 1958-05-29 1962-12-28 Hercules Powder Co Ltd Polymérisation de composés époxydés
DE2615061A1 (de) 1976-04-05 1977-10-06 Wolfgang Dr Med Wagner Injektionsverfahren und -vorrichtungen
US4252159A (en) 1979-04-02 1981-02-24 Maki Eugene B Dosage device
DE3501534A1 (de) 1984-09-22 1986-05-15 Walter Ing.(grad.) 7758 Meersburg Holzer Verfahren und vorrichtung zum dosieren von insulin oder aehnlichen langzeitmedikamenten
DE3875075D1 (de) 1987-11-25 1992-11-05 Siemens Ag Dosiergeraet zum gesteuerten injizieren von fluessigkeiten aus einem vorratsbehaelter in einen organismus.
EP0569618B1 (de) 1992-05-12 1997-01-02 Siemens-Elema AB Dosiergerät zur gesteuerten Abgabe einer Flüssigkeit
US7651845B2 (en) 2004-05-13 2010-01-26 The Regents Of The University Of California Method and apparatus for glucose control and insulin dosing for diabetics
US8106093B2 (en) * 2004-07-02 2012-01-31 Baylor Research Institute Glycogen or polysaccharide storage disease treatment method
US8251904B2 (en) 2005-06-09 2012-08-28 Roche Diagnostics Operations, Inc. Device and method for insulin dosing
US20070203235A1 (en) * 2006-02-28 2007-08-30 Rosales Francisco J Method for preventing or treating anemia
NZ555163A (en) * 2007-05-14 2010-05-28 Fonterra Co Operative Group Methods of immune or hematological enhancement, inhibiting tumour formation or growth, and treating or preventing cancer, cancer symptoms, or the symptoms of cancer treatments
DE102007055636A1 (de) 2007-11-21 2009-05-28 Robert Bosch Gmbh Medikamenten-Dosiervorrichtung zum Verabreichen eines flüssigen Medikaments
US20120072236A1 (en) 2010-08-06 2012-03-22 Benjamin Atkin Insulin pen data recording and transmission device
CN203915611U (zh) 2011-02-09 2014-11-05 贝克顿·迪金森公司 与输注基部附接的套节及用于传送药物的传送系统
US9561206B2 (en) * 2015-01-07 2017-02-07 The United States Of America, As Represented By The Secretary Of The Navy Use of heptadecanoic acid (C17:0) to detect risk of and treat hyperferritinemia and metabolic syndrome
US10307388B2 (en) 2016-12-29 2019-06-04 The United States Of America As Represented By The Secretary Of The Navy Compositions and methods for diagnosis and treatment of inflammation

Also Published As

Publication number Publication date
US20180185315A1 (en) 2018-07-05
MX2020004767A (es) 2021-08-26
JP2018135318A (ja) 2018-08-30
CA3039591A1 (en) 2018-07-05
EP3922244A1 (en) 2021-12-15
JP7037367B2 (ja) 2022-03-16
US10238618B2 (en) 2019-03-26
EP3562481B1 (en) 2021-08-25
US20200022939A1 (en) 2020-01-23
ES2899635T3 (es) 2022-03-14
WO2018122407A1 (en) 2018-07-05
US20190201362A1 (en) 2019-07-04
EP3562481A1 (en) 2019-11-06

Similar Documents

Publication Publication Date Title
MX2018000013A (es) Composiciones y metodos para diagnosis y tratamiento de anemia.
MX2021001091A (es) Compuestos para usarse en el tratamiento o mejoramiento de la enfermedad de huntington.
BR112017003658A2 (pt) composto, mistura, métodos para tratamento de uma doença e para inibição de uma glicosidase, e, composição farmacêutica.
SG11201901061QA (en) Heterocyclic compound
EA201891063A1 (ru) Производные дигидроимидазопиразинона, применимые в лечении рака
MY198613A (en) Nitrobenzyl derivatives of anti-cancer agents
CN106536480A8 (zh) 吡咯烷‑2,5‑二酮衍生物、药物组合物及用作ido1抑制剂的方法
MX2020001757A (es) Compuestos, sales de los mismos y metodos para el tratamiento de enfermedades.
MY197698A (en) Oxysterols and methods of use thereof
EA201491968A1 (ru) Производные имидазотиадиазола и имидазопиридазина в качестве ингибиторов активируемых протеазой рецепторов 4 (par4) для лечения агрегации тромбоцитов
CL2015002334A1 (es) Modificador del sabor dulce
CL2017001650A1 (es) Derivados de 5-[(piperazina-1-yl)-3-oxo-propilo]-imidazolidina-2,4-dionan como inhibidores adamts para el tratamiento oesteoartritis.
EA201791182A1 (ru) Новые производные 2'- и/или 5'-аминокислотных эфиров фосфороамидатов 3'-дезоксиаденозина в качестве противораковых соединений
EA201890767A1 (ru) C4-модифицированные производные олеаноловой кислоты для ингибирования il-17 и других применений
MX2016012835A (es) Composiciones y metodos para tratar las espinillas.
BR112016021648A2 (pt) novos compostos
BR112018006545A2 (pt) ?composto, composição farmacêutica, combinação, uso de um composto, e, método para tratamento de uma doença ou condição?
PH12017500007A1 (en) Quinolizinone derivatives as p13k inhibitors
EA033342B1 (ru) Пирролидинкарбоксамидо производные и способы их получения и их применение
PH12017501735A1 (en) Novel heterocyclic compound, method for preparing the same, and pharmaceutical composition comprising the same
BR112016021656A2 (pt) inibidores das vias de sinalização de wnt
PH12016502568A1 (en) Novel heterocyclic compound
PH12015502746A1 (en) Prodrug derivatives of substituted triazolopyridines
EA201692045A1 (ru) Производное фенантролинфосфоновой кислоты и способ его получения и применения
EA201591449A1 (ru) Способы получения противораковых композиций